Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Cash (2016 - 2025)

Mimedx (MDXG) has disclosed Change in Cash for 15 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 53.94% to $24.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.7 million through Dec 2025, up 175.27% year-over-year, with the annual reading at $61.7 million for FY2025, 175.27% up from the prior year.
  • Change in Cash hit $24.0 million in Q4 2025 for Mimedx, up from $23.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $24.0 million in Q4 2025 to a low of -$33.5 million in Q1 2024.
  • Historically, Change in Cash has averaged $3.5 million across 5 years, with a median of $1.4 million in 2023.
  • Biggest five-year swings in Change in Cash: plummeted 1316.09% in 2022 and later skyrocketed 1767.82% in 2024.
  • Year by year, Change in Cash stood at -$3.5 million in 2021, then plummeted by 106.21% to -$7.3 million in 2022, then skyrocketed by 111.5% to $836000.0 in 2023, then surged by 1767.82% to $15.6 million in 2024, then surged by 53.94% to $24.0 million in 2025.
  • Business Quant data shows Change in Cash for MDXG at $24.0 million in Q4 2025, $23.2 million in Q3 2025, and $12.4 million in Q2 2025.